Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate.
Measurement by radioimmunoassay of plasma norethisterone (NE) has been used to compare the bioavailability of tablets containing ethynodiol diacetate (EDA) with that of a standard oral solution of this progestogen in 12 normal women. The tablets investigated were from three batches which showed different in vitro dissolution rates. There were no significant differences in the bioavailability of the tablet formulations, which were essentially bioequivalent to the solution. Peak blood levels of NE were reached within 4h of EDA administration in solution or tablets. After the peak, NE plasma levels declined in two phases, with a mean terminal elimination half lives of 4 to 6.9h. The pharmacokinetics of NE after EDA administration showed some similarity to those observed by other workers after oral doses of NE itself.
D000328:Adult; D001682:Biological Availability; D005040:Ethynodiol Diacetate / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D009640:Norethindrone / Q000097:blood*
D005040:Ethynodiol Diacetate; D009640:Norethindrone